The global demand for effective obesity treatments has been surging, with a market size projected to reach USD 60.53 billion by 2030, yet latest therapies including GLP-1 receptor agonists (GLP-1RAs) ...
A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...
In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...
Repertoire Immune Medicines partners with Eli Lilly to develop tolerizing therapies for autoimmune diseases, receiving $85 ...
A new study reveals a critical vulnerability in a brain receptor targeted by a rare autoimmune disease. Researchers have ...
Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, is ...
Wegovy pills are now available in the U.S., offering a prescription-based, convenient alternative for weight management ...
THE gut microbiome was shown to predict how well patients with Type 2 diabetes responded to newer glucose-lowering therapies ...
Classically, the study of pharmacokinetics (PK) has centered on hepatic metabolism and renal excretion as the primary ...
Shattuck Labs (STTK) stock rises as Piper Sandler starts coverage with an Overweight rating and a $15 target, citing upcoming ...
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are ...
Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results